Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Toronto-Dominion Bank — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.42 (market cap $6.04B), while Toronto-Dominion Bank trades at $114.14 (market cap $185.79B). The key difference: Toronto-Dominion Bank is far larger — about 30.8× Iovance Biotherapeutics Inc. Common Stock's market cap, and Toronto-Dominion Bank pays a 2.84% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Toronto-Dominion Bank for 84 Days on average.
| IOVA | TD | |
|---|---|---|
Market Cap | $6.04B | $185.79B |
Volume | 14,805,993 | 3,263,867 |
Sector | Health | Financials |
52-Week High | $14.82 | $124.80 |
52-Week Low | $1.81 | $78.32 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $5.97B | $559.06B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TD stock trades at $113.87, down 3.65% on the day, with bearish technical signals but strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.98 exceeding expectations by 13.8%. Recent developments include a $10 billion share buyback program and a $108 billion commitment to Canadian infrastructure. Analyst consensus remains positive with 53% buy ratings and no sell recommendations.
TD presents a mixed investment case with strong profitability metrics (24.9% net margin, 13.6% ROE) offset by bearish technical indicators and volatile cash flow patterns. The stock's current valuation at 17.4x P/E appears reasonable given earnings growth, while the aggressive capital return program signals management confidence. Key risks include interest rate sensitivity and ongoing AML remediation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
